

[Home](#)[Background](#)[Members](#)[Secretariat](#)[Workgroups](#)[Internal](#)[News](#)[Events](#)[Links](#)[Contact Us](#)

IMPC Secretariat

In this preparatory phase a Secretariat has been established to develop a detailed operational plan for the IMPC with an expected launch by the end of 2011. The Secretariat will support the IMPC Steering Committee in developing the operational plan including:

- Assisting the Steering Committee with the development of an IMPC Operational Plan
- Establishing international workgroups comprising representatives from the participating centers, funders and external experts to provide advice to the Steering Committee on operational areas such as Phenotyping and Informatics
- Organising meetings and other workshops to engage the wider biomedical sciences community in the development of the IMPC programme

Secretariat Contacts:

Executive Director:

Mark Moore, PhD

Email: m.moore@wellcome.ac.uk

<http://www.mousephenotype.org>

Project and Communications Manager:

Joerg Rossbacher, PhD

Email: joerg.rossbacher@helmholtz-muenchen.de

<http://www.mouseclinic.de>

Perform the tasks and implement the decisions of the Steering Committee

Work closely with and support the Scientific Director of the IMPC

Organize and manage committees that are formed to provide guidance to the Steering Committee

Coordinate-facilitate working groups as an impartial person to help keep diverse groups working together

Manage the administrative and operational activities and obligations of the IMPC

Facilitate communication among all Steering Committee Members

Represent the IMPC at public meetings to foster community support, inform the public of IMPC activities and seek actively new IMPC members that share the vision and could contribute to the project.



[Home](#)[Background](#)[Members](#)[Secretariat](#)[Workgroups](#)[Internal](#)[News](#)[Events](#)[Links](#)[Contact Us](#)

IMPC Events

IMPC and KOMP2 Kickoff and KOMP Annual Meeting Washington DC, September 28-29, 2011

Infrafrontier Annual Meeting 2011, Rome, Italy, July 4-5, 2011

2011 Bio International Convention, June 27-30, 2011

held at the Walter E. Washington Convention Center, Washington DC, USA.

Mouse Genetics Conference 2011, Washington DC, June 21-27 2011

A joint conference of the International Mammalian Genome Society (IMGS), Complex Trait Community (CTC) and the Genetics Society of America (GSA) discussing hot topics in mouse research including Disease Models, Large Scale Resources, Preclinical Translation and System Genetics. <http://www.mousegenetics2011.org/>

Industry Liaison Workshop, London, April 7th 2011

A meeting to discuss IMPC-Industry collaboration will be held on April 7, 2011 at the Wellcome Trust, London, UK. Participants include representatives from Pharma, Biotech, Mouse Vendors and CROs, Platform and IT Providers, Academic and Government Research Organizations, Tech Transfer Officers and Specialist Consultants. Visit the [Industry Work Group](#) section.

EUMODIC Annual Meeting 2011, Barcelona, Spain, March 2-3

IMPC Phenotyping Work Group Meeting, Barcelona, February 28th - March 1st, 2011

A group of internal and external experts discussed the ideal test systems available for many disease areas and how to best arrange them into a phenotyping pipeline.





IMPC Phenotyping Work Group

The Phenotyping Work group consists of 5 to 6 experts from each participating member of the IMPC, along with additional external experts reflecting phenotyping expertise from the wider mouse, clinical, biotech and pharmaceutical communities. The Phenotyping Workgroup will advise the IMPC Steering Committee on the core phenotyping platforms that should be implemented as part of an IMPC primary phenotyping pipeline, taking account of the strategic needs for mouse models and the requirements of the wider biomedical, clinical, biotech and pharmaceutical communities. The work group will consider the development and inclusion of new phenotyping platforms, the timing of tests, test orders and cohort size. In addition they will advise on the statistical issues associated with the use of control cohorts, the identification of phenotypes and provide guidance on the likely costs of a core phenotyping pipeline.

Phenotype Work Group Report

A report from the IMPC Phenotyping workgroup is now available to download, and we welcome your comments and input. The report concludes by presenting a [draft IMPC phenotype pipeline](#) (see Figure 1 and 2). However, note that the draft pipeline is at this stage an amalgam of the key primary tests that following the discussions of the Phenotype Workgroup merited serious consideration for incorporation into a final IMPC pipeline. The draft presented in Fig. 1 and 2 is a starting point for further discussion and design of a final agreed pipeline. The establishment of the final IMPC pipeline will require additional review and iterations, particularly to take account of test density, inter-test perturbations and the minimisation of these effects.

Phenotyping Working Group Report PDF



[Click to View Draft Pipeline](#)



IMPC Working Groups

Informatics

- Coordinate with MPI2
- Develop Requirements Document

Mice

- Explore new ways to lower mouse costs
- Technology development

Tech Dev

- Form Tech Development Group
- First Tasks: Imaging Recommendation (&Pathology)
 - Embryonic Lethal Analysis

Phenotyping

- Develop final plan for IMPC Pipeline
- Operating plan for review of pipeline

Challenge Models

- Working groups in each area
- Devise how to test models at centers

Industry Outreach



IMPC

IMPC Industry Working Group

Allan Bradley, WTSI, Cambridge UK,
abradley@sanger.ac.uk

Martin Hrabe-deAngelis, GMC, Munich Germany,
hrabe@helmholtz-muenchen.de

Colin McKerlie, TCP, Toronto Canada,
colin.mckerlie@phenogenomics.ca

Mark Moore, NIH/IMPC, San Francisco USA,
mwmoore880@comcast.net

Tom Weaver (Chair), MRC Harwell, Oxford UK,
t.weaver@har.mrc.ac.uk





IMPC Industry Working Group

Remit:

- The working group is tasked to developing a strategy for liaising with Industry and making recommendations for consideration by the IMPC steering committee.

Goals:

- How the IMPC can best serve the needs of the biopharmaceutical industry.
- Communicate with industry about our program.
- Explore how industry can participate in the IMPC.
- Develop and implement an engagement plan.



Planned Activities

Draft Engagement Plan


- Consider Different Models
- Begin Discussing with Industry

Contact List (>100 so far)

Workshop (London, April 7th)

Sign-off By Steering Committee


Launch @ Bio2011 (Washington DC, July 2011)



IMPC Phenotyping



1b. Would the current tests reveal phenotypes that would motivate you to shift your own resources and to take mice and begin work on them in your lab?

If No, then why? Limited
Challenge
Models
(e.g.
infectious
agents)



Survey Summary Report

Question #2: Thinking beyond your laboratory, what do you see as the 3 essential tests, analyses, and/or examinations that would most likely reveal the utility of a mutant mouse line in your field? Two caveats: the numbers of mice used per test are limited to 5-10 and the tests must be high throughput (100's/y).




**MMRC Survey Conducted by
Kent Lloyd**



Survey Summary Report

What is missing?



**MMRC Survey Conducted by Kent Lloyd
>2000 e-mails and ~300 respondents**



Key Areas to Address

Cancer

- Need longer time line to study
- Fits with aging
- Challenge?

Aging

- Critical need cited in all surveys and workshops
- Strongly augments: Cancer, Cardiovascular, Metabolic, Neurodegeneration and Bone Research

Embryology

- ~30% KOs E.L.
- Very Specialized Skill Sets Req.
- Need HTP approach
- Meeting at TCP April 9-10

Immunology

- Key area cited in surveys
- Many groups cannot perform F.A.C.S.
- Challenge models strongly requested

IMPC Phenotyping Issues

- Core group of tests at all centres
- Agreed upon minimum cohort size (7?)
- Test and recommend additions to or dropping phenotypic tests from the pipeline
- Groups are encouraged to add tests to the phenotyping platform where possible
- Each centre is encouraged to incorporate a challenge assay or assays to the platform: plan and coordination?
- Each centre should develop networks of collaborators
- MRI and/or micro CT likely to be added
- Incorporate study of embryonic lethals
- SOPs for current tests, manage, QC and versions
- CONTROLS: WT littermates, WT representation or C57BL/6N

IMPC Organization and Structure

- A good deal accomplished
- Much more to do
- We take volunteers

Governance

- The IMPC has grown significantly in the past 2 years (doubling in the past 4 months)
- Consider an executive committee or revamped steering committee to be more efficient
- Need to finalize formal governance
- Expand IMPC to include smaller groups that add value
- Discussions will continue and plan for adoption by late fall